Avalo Therapeutics (AVTX) insider schedules 679-share stock sale after option exercise
Rhea-AI Filing Summary
Avalo Therapeutics, Inc. (AVTX) reports that an affiliate, Morgan Stanley Smith Barney LLC Executive Financial Services, intends to sell common stock on behalf of a party identified in the notice. The planned transaction covers 679 shares of common stock in connection with an exercise of stock options for cash on 08/10/2026.
The notice also lists prior common stock sales for Mittie Doyle under a Rule 10b5-1 trading plan over the past three months, including transactions on 05/15/2026, 05/28/2026, 06/23/2026, 06/30/2026, and 07/27/2026 with share counts ranging from 679 to 4,654 shares.
Positive
- None.
Negative
- None.
Key Figures
Planned shares to be sold: 679 shares
Planned transaction value: $12,439.28
Past sale 06/30/2026: 4,654 shares for $93,080.00
+2 more
5 metrics
Planned shares to be sold
679 shares
Common stock tied to stock option exercise for cash on 08/10/2026
Planned transaction value
$12,439.28
Aggregate value associated with 679 AVTX common shares
Past sale 06/30/2026
4,654 shares for $93,080.00
Rule 10b5-1 AVTX common stock sale for Mittie Doyle
Past sale 05/15/2026
3,000 shares for $56,280.00
Rule 10b5-1 AVTX common stock sale for Mittie Doyle
Past sale 07/27/2026
1,000 shares for $20,000.00
Rule 10b5-1 AVTX common stock sale for Mittie Doyle
Key Terms
Rule 10b5-1, Exercise of Stock Options, Form 144, Executive Financial Services
4 terms
Rule 10b5-1 regulatory
"10b5-1 Sales for MITTIE DOYLE 1500 Liberty Ridge Drive, Suite 321"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Exercise of Stock Options financial
"Common | 08/10/2026 | Exercise of Stock Options | Issuer"
Form 144 regulatory
"144: Securities To Be Sold Common | 08/10/2026"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Executive Financial Services financial
"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stock sale is being reported for AVTX in this Form 144 notice?
The notice reports an intent to sell 679 shares of Avalo Therapeutics (AVTX) common stock. The shares are tied to an exercise of stock options for cash on 08/10/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services.
How is the AVTX stock being acquired before the planned sale on 08/10/2026?
The AVTX common stock is being acquired through an exercise of stock options on 08/10/2026. The notice states that the acquisition method is an option exercise paid in cash, after which the 679 shares are intended to be sold.
What past Rule 10b5-1 sales for AVTX stock by Mittie Doyle are disclosed?
The notice lists Rule 10b5-1 sales of AVTX common stock for Mittie Doyle on 05/15/2026, 05/28/2026, 06/23/2026, 06/30/2026, and 07/27/2026, with individual transactions ranging from 679 to 4,654 shares.
What were the largest recent AVTX stock sales under the 10b5-1 plan?
The largest reported recent sale under the Rule 10b5-1 plan is 4,654 AVTX shares on 06/30/2026 for $93,080.00. Another notable sale is 3,000 shares on 05/15/2026 for $56,280.00.
Who is identified in connection with the recent AVTX 10b5-1 stock sales?
The recent AVTX stock sales under a Rule 10b5-1 plan are identified as being for Mittie Doyle. Multiple transactions in AVTX common stock are listed for this individual between 05/15/2026 and 07/27/2026.